Department of Pediatrics, Dalhousie University and IWK Health Centre, Halifax, NS, Canada.
Expert Rev Clin Immunol. 2011 Jul;7(4):419-28. doi: 10.1586/eci.11.34.
Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, features recurrent episodes of inflammation of the GI tract. The treatment of inflammatory bowel disease is aimed at breaking the cycle of relapsing and remitting inflammation by inducing and maintaining remission. Systemically active conventional corticosteroids have long played a role in the induction of remission in both Crohn's disease and ulcerative colitis, however, their long-term use can lead to adverse systemic effects. Budesonide, a synthetic steroid, has potent local anti-inflammatory effects and limited systemic bioavailability making it an appealing therapeutic option. Ulcerative colitis with predominantly distal disease may be treated with topical budesonide, however, novel oral controlled-release formulations have also been developed to allow for treatment of the entire colon. This article summarizes the use of budesonide in the management of inflammatory bowel disease.
炎症性肠病，包括克罗恩病和溃疡性结肠炎，其特征是胃肠道反复发作炎症。炎症性肠病的治疗旨在通过诱导和维持缓解来打破反复发作和缓解的炎症循环。全身性活性常规皮质类固醇在诱导克罗恩病和溃疡性结肠炎缓解方面一直发挥着重要作用，然而，它们的长期使用会导致不良的全身影响。布地奈德是一种合成类固醇，具有强大的局部抗炎作用和有限的全身生物利用度，使其成为一种有吸引力的治疗选择。主要累及远端结肠的溃疡性结肠炎可采用局部布地奈德治疗，然而，也开发了新型口服控释制剂，以允许治疗整个结肠。本文总结了布地奈德在炎症性肠病治疗中的应用。
